FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3093376462> ?p ?o ?g. }

• W3093376462 endingPage "A906" @default.
• W3093376462 startingPage "A906" @default.
• W3093376462 abstract "SESSION TITLE: Medical Student/Resident Critical Care Posters SESSION TYPE: Med Student/Res Case Rep Postr PRESENTED ON: October 18-21, 2020 INTRODUCTION: Posterior reversible encephalopathy syndrome (PRES) is a clinical radiographic syndrome characterized by seizures, visual disturbances and altered mental status. MRI of the brain exhibits vasogenic edema. Failure of autoregulation of cerebral arteries and disruption of the endothelium of the blood-brain-barrier are the two mechanisms underlying vasogenic edema. PRES has many triggers, including the use of chemotherapeutic agents. We present the case of a patient on treatment with paclitaxel/carboplatin, diagnosed with PRES, with radiographic evidence of both vasogenic and cytotoxic edema. CASE PRESENTATION: A 61-year-old male diagnosed with squamous cell carcinoma of the lung, recently started on Carboplatin and Paclitaxel, presented to the hospital with altered mental status. He was afebrile, blood pressure 117/77 mmHg, pulse 105 and respiratory rate 24. Physical exam revealed an unresponsive male in respiratory distress. Initial CT brain and blood investigations were unremarkable. He was admitted to the ICU and intubated for failure to protect his airway. MRI brain, revealed hyperintensities on T2-weighted and FLAIR imaging with patchy restricted diffusion involving bilateral fronto-parieto-occipital cortex typical of vasogenic edema and PRES. During further workup, he was found to have a left atrial thrombus from tumor invasion. He was started on anticoagulation and loaded with levetiracetam. He was noted to have dense hemiparesis two days later and underwent CT angiography of the brain which confirmed vasogenic with cytotoxic edema and diffusely increased vascularity as a consequence of decreased cerebral autoregulation. He regained consciousness and tolerated extubation, with complete resolution of hemiparesis. Following extubation, he was found to have visual disturbances which resolved and he was discharged with no neurological deficits. DISCUSSION: PRES with both vasogenic and cytotoxic edema is rare. Our patient had a recent MRI brain and PET/CT for tumor staging, which was negative for brain metastasis. There was a lack of evidence supporting an alternative cause for development of cytotoxic edema making PRES the most likely cause. Several studies have reported cytotoxic edema in PRES. In them, endothelial dysfunction seems to cause both vasogenic and cytotoxic edema occurs in PRES, with areas surrounding marked vasogenic edema usually progressing to cytotoxic edema. CONCLUSIONS: There is increasing evidence for development of PRES with several chemotherapy agents like carboplatin/paclitaxel. It may be characterized by vasogenic as well as cytotoxic edema. Cytotoxic edema is probably related to local decreased perfusion and arteriolopathy. Further research is warranted to understand the pathophysiologic mechanisms involved. It is important to recognize symptoms early and have a high clinical suspicion in spite of radiological evidence of cytotoxic edema, as PRES generally has an excellent prognosis with complete resolution. Reference #1: Janjua, T. K., Hassan, M., Afridi, H. K., & Zahid, N. A. (2017). Oxaliplatin-induced posterior reversible encephalopathy syndrome (PRES). BMJ case reports, 2017, bcr2017221571. https://doi.org/10.1136/bcr-2017-221571 Reference #2: Roth, C., & Ferbert, A. (2011). The posterior reversible encephalopathy syndrome: what's certain, what's new?. Practical neurology, 11(3), 136 -144. https://doi.org/10.1136/practneurol-2011-000010 Reference #3: Gao, B., Yu, B. X., Li, R. S., Zhang, G., Xie, H. Z., Liu, F. L., & Lv, C. (2015). Cytotoxic Edema in Posterior Reversible Encephalopathy Syndrome: Correlation of MRI Features with Serum Albumin Levels. AJNR. American journal of neuroradiology, 36(10), 1884 -1889. https://doi.org/10.3174/ajnr.A4379 DISCLOSURES: No relevant relationships by Bilal Bangash, source=Web Response No relevant relationships by Michael Buscher, source=Web Response No relevant relationships by Jay Parekh, source=Web Response No relevant relationships by Prachi Pednekar, source=Web Response No relevant relationships by Pranav Sharma, source=Web Response" @default.
• W3093376462 created "2020-10-22" @default.
• W3093376462 creator A5004976796 @default.
• W3093376462 creator A5062114603 @default.
• W3093376462 creator A5075628539 @default.
• W3093376462 creator A5081401590 @default.
• W3093376462 creator A5083445956 @default.
• W3093376462 date "2020-10-01" @default.
• W3093376462 modified "2023-09-27" @default.
• W3093376462 title "CYTOTOXIC EDEMA IN CHEMOTHERAPY-ASSOCIATED POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME" @default.
• W3093376462 doi "https://doi.org/10.1016/j.chest.2020.08.842" @default.
• W3093376462 hasPublicationYear "2020" @default.
• W3093376462 type Work @default.
• W3093376462 sameAs 3093376462 @default.
• W3093376462 citedByCount "1" @default.
• W3093376462 countsByYear W30933764622020 @default.
• W3093376462 crossrefType "journal-article" @default.
• W3093376462 hasAuthorship W3093376462A5004976796 @default.
• W3093376462 hasAuthorship W3093376462A5062114603 @default.
• W3093376462 hasAuthorship W3093376462A5075628539 @default.
• W3093376462 hasAuthorship W3093376462A5081401590 @default.
• W3093376462 hasAuthorship W3093376462A5083445956 @default.
• W3093376462 hasBestOaLocation W30933764621 @default.
• W3093376462 hasConcept C126322002 @default.
• W3093376462 hasConcept C126838900 @default.
• W3093376462 hasConcept C143409427 @default.
• W3093376462 hasConcept C2776694085 @default.
• W3093376462 hasConcept C2777318445 @default.
• W3093376462 hasConcept C2777605182 @default.
• W3093376462 hasConcept C2778239845 @default.
• W3093376462 hasConcept C2778621155 @default.
• W3093376462 hasConcept C2779662492 @default.
• W3093376462 hasConcept C2781451048 @default.
• W3093376462 hasConcept C42219234 @default.
• W3093376462 hasConcept C71924100 @default.
• W3093376462 hasConceptScore W3093376462C126322002 @default.
• W3093376462 hasConceptScore W3093376462C126838900 @default.
• W3093376462 hasConceptScore W3093376462C143409427 @default.
• W3093376462 hasConceptScore W3093376462C2776694085 @default.
• W3093376462 hasConceptScore W3093376462C2777318445 @default.
• W3093376462 hasConceptScore W3093376462C2777605182 @default.
• W3093376462 hasConceptScore W3093376462C2778239845 @default.
• W3093376462 hasConceptScore W3093376462C2778621155 @default.
• W3093376462 hasConceptScore W3093376462C2779662492 @default.
• W3093376462 hasConceptScore W3093376462C2781451048 @default.
• W3093376462 hasConceptScore W3093376462C42219234 @default.
• W3093376462 hasConceptScore W3093376462C71924100 @default.
• W3093376462 hasIssue "4" @default.
• W3093376462 hasLocation W30933764621 @default.
• W3093376462 hasOpenAccess W3093376462 @default.
• W3093376462 hasPrimaryLocation W30933764621 @default.
• W3093376462 hasRelatedWork W2102020001 @default.
• W3093376462 hasRelatedWork W2108441005 @default.
• W3093376462 hasRelatedWork W2138552353 @default.
• W3093376462 hasRelatedWork W2314115817 @default.
• W3093376462 hasRelatedWork W2326253238 @default.
• W3093376462 hasRelatedWork W2350445292 @default.
• W3093376462 hasRelatedWork W2794299717 @default.
• W3093376462 hasRelatedWork W2997616292 @default.
• W3093376462 hasRelatedWork W1556208436 @default.
• W3093376462 hasRelatedWork W2336957092 @default.
• W3093376462 hasVolume "158" @default.
• W3093376462 isParatext "false" @default.
• W3093376462 isRetracted "false" @default.
• W3093376462 magId "3093376462" @default.
• W3093376462 workType "article" @default.